Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News

The Lead

AstraZeneca Releases Phase 4 Brilinta Data

September 2, 2014 3:35 pm | News | Comments

AstraZeneca announced the results of the Phase 4 ATLANTIC study, which indicates that the profile of Brilinta/Brilique (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. Read more...

FDA Names Myelofibrosis Treatment an Orphan Drug

September 2, 2014 3:25 pm | News | Comments

Promedior Inc. announced that the FDA has granted an orphan drug designation for PRM-151, for...

Ipsen's Somatuline Gets Priority Review

September 2, 2014 3:16 pm | News | Comments

Ipsen N.A. announced that the FDA has accepted and granted priority review of its supplemental...

Amgen Submits MAA for Melanoma Treatment

September 2, 2014 2:59 pm | News | Comments

Amgen announced the submission of a Marketing Authorization Application to the European...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Bayer Extends Xarelto Investigation to 275,000 Patients

September 2, 2014 10:24 am | News | Comments

Bayer HealthCare and its development partner Janssen Research & Development LLC announced an expansion of the global clinical development program for the oral Factor Xa inhibitor rivaroxaban for the prevention of potentially deadly blood clots in patients at risk of arterial thromboembolism. Read more...

Daiichi Sankyo Expands Drug Discovery Collaboration in Europe

September 2, 2014 10:12 am | News | Comments

Daiichi Sankyo Co. Ltd. announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Program 2014, a collaborative drug discovery initiative for universities and research institutes in Europe. Read more...   

Novo Nordisk Discontinues Inflammatory Disorder Activities

September 2, 2014 10:00 am | News | Comments

Novo Nordisk announced a decision to discontinue all its research and development (R&D) activities within inflammatory disorders. Read more...                              

Advertisement

EC Approves Allergan's Ozurdex for DME

September 2, 2014 9:52 am | News | Comments

Allergan Inc. announced that the European Commission has extended the Marketing Authorization for Ozurdex to treat adult patients with visual impairment due to diabetic macular edema (DME). Read more...              

Heart Failure Drug Cuts Deaths, Hospitalizations by 20%

September 2, 2014 9:44 am | News | Comments

A new study reports one of the biggest potential advances against heart failure in more than a decade— a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20%. Read more...          

Synthesis Produces New Antibiotic

August 29, 2014 2:00 pm | News | Comments

A  collaboration at Rice University has led to the total synthesis of a recently discovered natural antibiotic. The laboratory recreation of a fungus-derived antibiotic, viridicatumtoxin B, may someday help bolster the fight against bacteria that evolve resistance to treatments in hospitals and clinics around the world. Read more...

Researchers Investigating New MS Treatment

August 28, 2014 2:00 pm | News | Comments

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in Phase 1 clinical trials, according to a new study. The Phase 1 studies were the first to test the drug candidate in humans. Read more...     

GSK-NIH Ebola Vaccine to Enter Safety Testing

August 28, 2014 2:00 pm | by Seth Borenstein, AP Science Writer | News | Comments

Federal researchers next week will start testing humans with an experimental vaccine to prevent the deadly Ebola virus. The NIH announced today that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GSK. Read more...

Advertisement

FDA Approves Generic Megace from TWi

August 28, 2014 9:45 am | News | Comments

TWi Pharmaceuticals Inc. announced that it has received final approval from the FDA on its Abbreviated New Drug Application for megestrol acetate 125mg/ml oral suspension, the generic equivalent to Par Pharmaceutical's Megace ES. Read more...   

Daiichi Sankyo Signs Hep B Vaccine Agreement

August 28, 2014 9:40 am | News | Comments

Daiichi Sankyo Co. Ltd. announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute  for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen. Read more...       

Allergan Sets Date for Special Shareholder Meeting

August 27, 2014 3:28 pm | by The Associated Press | News | Comments

Botox maker Allergan Inc. has set a date for a special meeting at which its shareholders will consider replacing most of its board, but it doesn't want the main proponents of that move to participate. Read more...           

FDA Clears Asterias to Begin Stem Cell Trial

August 27, 2014 3:08 pm | News | Comments

Asterias Biotherapeutics Inc. has received clearance from the FDA to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. Read more...               

Potential Therapy for Sudan Ebola Strain May Contain Future Outbreaks

August 27, 2014 2:45 pm | News | Comments

Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies. One of the most lethal strains is the Sudan ebolavirus (SUDV). In a new study, researchers report a possible therapy that could someday help treat patients infected with SUDV. Read more...

Advertisement

Amgen Heart Failure Drug Gets Priority Review

August 27, 2014 2:32 pm | News | Comments

Amgen announced the FDA has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node. Read more...   

Merck Serono Breaks Ground on New China Facility

August 27, 2014 11:09 am | News | Comments

Merck Serono, the biopharmaceutical division of Merck, held the groundbreaking ceremony for its new pharmaceutical manufacturing facility in Nantong, China. Read more...                       

EC Approves BMS Drug as Hep C Combo Treatment

August 27, 2014 11:03 am | News | Comments

Bristol-Myers Squibb Co. announced that the European Commission has approved Daklinza (daclatasvir) for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults. Read more...

FDA Approves Additional Promacta Indication

August 26, 2014 3:14 pm | News | Comments

GSK announced that the FDA has approved a supplemental New Drug Application for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). Read more...

Alkermes Launches Phase 1 Pain Treatment Study

August 26, 2014 3:08 pm | News | Comments

Alkermes plc announced the initiation of a Phase 1 clinical study of ALKS 7106, a proprietary, novel, oral, small-molecule drug candidate for the treatment of pain. Read more...                       

Kite Pharma's Lymphoma Drug Excels in Trial

August 26, 2014 3:03 pm | News | Comments

Shares of Kite Pharma surged before markets opened Tuesday after the drug developer detailed promising results for its most advanced product, a potential treatment for an aggressive form of non-Hodgkin's lymphoma. Read more...       

Pfizer, Merck to Explore Novel Anti-Cancer Combo

August 26, 2014 2:55 pm | News | Comments

Pfizer Inc. and Merck & Co. Inc. announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab. Read more...   

Cancer-Fighting Drugs Might Also Stop Malaria Early

August 26, 2014 2:47 pm | News | Comments

Scientists searching for new drugs to fight malaria have identified a number of compounds- some of which are currently in clinical trials to treat cancer- that could add to the anti-malarial arsenal. Read more...            

Drug Cured 16 of 16 Monkeys with Viral Ebola Relative

August 26, 2014 11:31 am | by Cynthia Fox, Science Editor | Articles | Comments

An experimental drug saved the lives of 16 of 16 monkeys with the Marburg virus, a killer near-indistinguishable from Ebola, just as symptoms broke out, said a new study. Read more...                   

Cardiome, Eurolab Partner on Brinavess Distribution

August 26, 2014 11:00 am | News | Comments

Cardiome Pharma Corp. announced that its subsidiary, Correvio International Sàrl, has entered into an agreement with Eurolab Especialidades Medicinales de Eurofar S.R.L. to sell and distribute Brinavess exclusively in Argentina. Read more…    

New Ebola Vaccine Study Delivers Promising Results

August 26, 2014 10:44 am | News | Comments

Immunovaccine Inc. announced positive results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Read more...

Avanir Launches Phase 2 MDD Drug Study

August 26, 2014 10:23 am | News | Comments

Avanir Pharmaceuticals Inc. announced the enrollment of the first patient into a Phase 2 study to evaluate the efficacy, safety and tolerability of AVP-786 for the adjunctive treatment of major depressive disorder (MDD). Read more...     

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading